Core Viewpoint - The article highlights the recent advancements in peripheral vascular intervention technology, particularly focusing on the approval and features of the Jin Can™ peripheral vascular balloon dilation catheter developed by Bofei Medical, marking a significant breakthrough in the treatment of complex vascular diseases [1][17]. Product Features - The Jin Can™ catheter features a unique design with a nickel-titanium memory alloy metal mesh structure and a spiral metal mesh design at the tip, which reduces the risk of thrombosis and ensures safe retraction [3][17]. - Enhanced flexibility is achieved through an intermittent nickel-titanium wire mesh design, allowing the catheter to navigate through curved lesions effectively [3]. Market Overview - Peripheral artery disease, characterized by local stenosis or occlusion of peripheral arteries, is expected to see an increase in intervention procedures due to rising health awareness and living standards in China [5]. - The market for peripheral artery intervention balloons and stents in China is projected to grow to 6.8 billion yuan by 2030, driven by the increasing volume of procedures [5]. Market Growth Rates - The growth rates for balloon and stent markets from 2017 to 2030 are as follows: - Balloons: 30.5% (2017-2021), 21.5% (2021-2025E), 13.8% (2025E-2030E) - Stents: 14.7% (2017-2021), 11.0% (2021-2025E), 5.7% (2025E-2030E) - Overall market: 21.7% (2017-2021), 16.8% (2021-2025E), 11.0% (2025E-2030E) [7]. Competitive Landscape - The domestic PTCA balloon catheter market is characterized by significant competition, with major players including Demark, MicroPort, Lepu Medical, and Bofei Medical. However, foreign companies hold over 60% of the market share, with Boston Scientific and Medtronic accounting for nearly 50% [8][9]. - There remains substantial room for domestic manufacturers to increase their market share in the PTCA balloon catheter segment [9]. Recent Approvals - Bofei Medical's Jin Can™ balloon catheter was approved for market entry in June 2025, and the company has developed a comprehensive product matrix for peripheral vascular interventions [17]. - Other recent approvals include the SeaDragon™ ultra-high-pressure balloon catheter by Lanpai Medical and the peripheral balloon catheter by Youdebang Medical, both designed for various vascular applications [12][15]. Company Background - Bofei Medical, established in 2020, has developed a complete product line for peripheral vascular interventions, including the Jin Can™ catheter and other related products [17]. - Lanpai Medical, founded in 2002 and listed on the Shenzhen Stock Exchange, is a leading medical device company with a diverse portfolio covering various medical fields, including cardiovascular interventions [18].